Enhanced antibody-dependent cellular cytotoxicity (ADCC) of allogeneic g-NK cell product driven in part by faster cell migration and a higher frequency of synapse formation
Applications of dynamic single-cell analysis include screening donors, enhancing ADCC, quantifying potency/viability, and more. Presenters represent CellChorus, Indee Labs, and Indapta Therapeutics.
CAR27 NK cells with CD28-based costimulation were approximately three times more likely to exhibit serial killing behavior and resulted in significantly better long-term cytotoxicity, polyfunctionality, and survival in animals
The National Center for Advancing Translational Sciences (NCATS) of the NIH has awarded CellChorus and the University of Houston an STTR Fast-Track grant to advance the development of its Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) platform for dynamic single-cell analysis.
Researchers published data in Nature Cancer identifying a subset of CAR T-cells within axicabtagene ciloleucel (axi-cel) products that result in patient responses. Key results—including single-cell migration, killing, and serial killing—were generated with the company’s Time-lapse Imaging In Nanowell Grids (TIMING™) platform, which applies artificial intelligence (AI) to evaluate cells over time.
The National Center for Advancing Translational Sciences (NCATS) of the NIH has awarded CellChorus an SBIR Fast-Track grant to advance the development of its Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) platform for dynamic single-cell analysis.
Precision Medicine in Immunotherapy session will include Rebecca Berdeaux, PhD, the VP of Science at CellChorus
Scientsists applied TIMING to quantify motility, contact dynamics, spontaneous death, activation-induced cell death, and cytotoxicity of cells, including CAR-T cell behavior before and after activation by a target cell. Compared with nucleofected cells, hydroporated cells exhibited significantly less activation-induced cell death (AICD) and improved motility as measured by the speed at which CAR-T cells migrated to subsequent target cells after being activated and forming synapses with target cancer cells.
Dr. Last is EVP & COO of Bio-Rad Laboratories. He brings more than three decades worth of experience leading a variety of life sciences organizations.
Award recognizes use of AI to evaluate immune cell function and performance to improve the development and delivery of therapeutics
The Challenge seeks applicants with research, development and manufacturing projects that will benefit from dynamic single-cell analysis and present a significant innovation or advance in human health. Applications will be accepted through December 10, 2023
CellChorus expands its commercial and technical advisory board with industry experts across artificial intelligence, life science commercialization, oncology, and infectious diseases
International Society for Cell & Gene Therapy meeting in Houston includes CellChorus presentations on EV secretion and TIMING™ for manufacturing
TechCruch has selected CellChorus to present in the Startup Battlefield 200 program at TechCrunch Disrupt
CellChorus has joined NVIDIA Inception, a program designed to nurture startups revolutionizing industries with advancements in artificial intelligence (AI) and data sciences.
The U.S. National Science Foundation (NSF) has awarded CellChorus a Small Business Innovation Research (SBIR) grant to advance development of its Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) platform for dynamic single-cell analysis. The Phase I grant will be used to develop novel microscale arrays to support scaling dynamic single-cell analysis across the life sciences industry.
The National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) has awarded CellChorus a Small Business Innovation Research (SBIR) Fast-Track grant to advance the development of its Time-lapse Imaging Microscopy In Nanowell Grids™ (TIMING™) platform for dynamic single-cell analysis.
Evaluating individual cells with an integrated methodology to identify single cancer cells with differences in extracellular vesicle (EV) secretion and further link EV secretion to their transcriptome.
TIMING™ data from the CellChorus early access program also demonstrated that FUSE394 preserves T cell motility and healthy morphology and promotes 50% more synapse formation than a non-decoupled control.
CellChorus was named one of five BioTools Innovator finalists. The top five companies will present on October 13 at the BioTools Innovator Capstone event during the Cell & Gene Meeting on the Mesa.
TIMING™ assays provide direct functional evaluation of exhaustion and killing by natural killer cells that had ingested tumor antigens by trogocytosisin. The research led to a novel dual-targeting approach to prevent CAR-NK cell exhaustion and tumor escape.
Dr. Berdeaux is an expert in cell signaling, energy metabolism, and skeletal muscle regeneration. Prior to joining CellChorus, she focused on research and medical education as a tenured Associate Professor of Integrative Biology and Pharmacology with McGovern Medical School at UTHealth Houston, where she retains a faculty position and laboratory.
The Journal of Clinical Investigation has published clinical data in a manuscript by scientists from one of the first companies with an approved CAR-T cell therapy, a comprehensive cancer center, the University of Houston, and CellChorus®. The publication, “Multidimensional single-cell analysis identifies a role of CD2-CD58 interactions for clinical antitumor T cell responses,” demonstrates the potential for identifying patients that are likely to respond to a form of cancer immunotherapy called chimeric antigen receptor (CAR) T-cell therapy.
Varadarajan and his partners at The University of Texas MD Anderson Cancer Center profiled the dynamic interactions between T cells that comprise patient infusion products and tumors, using the TIMING (Timelapse Imaging Microscopy In Nanowell Grids) method.
CellChorus has been selected as an Innovation Challenge winner in the healthcare category for the 2022 Defense TechConnect Innovation Summit & Expo.
CellChorus has been selected for the 2022 BioTools Innovator Accelerator. BioTools Innovator is the first accelerator focused on life science tools and diagnostics to advance cutting-edge research and improve human health.
Industry experts Rebecca Berdeaux, PhD, Dimitrios Kontoyiannis, MD, PhD, and Laurence Cooper, MD, PhD to advise on CellChorus growth initiatives
Julien Bradley is the CEO of RedShift BioAnalytics and held leadership roles at Quanterix, Thermo Fisher Scientific, and Ahura Scientific
Scientists from CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform over time, today published a report demonstrating that cytotoxic T lymphocytes (CTLs) targeting a conserved SARS-CoV-2 spike epitope are efficient serial killers.
CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform over time, announced today that it will present at the 2022 MIT Health Science Technologies Conference: The Future of Cell & Gene Therapies.
